Creative Medical Technology Holdings, Inc.
CELZHealthcare|Biotechnology|US
$0.62
+0.02 (+2.65%)
DCF Value
$2.94
Tangible Book / Share
$1.05
Cash / Share
$1.03
About
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
Stock Price
-79.1%(1Y)
1M
-27.7%
3M
-56.2%
6M
-73.1%
YTD
-68.3%
1Y
-81.0%
3Y
-85.3%
5Y
-99.1%
Pipeline Summary
4 total trials2
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
Available: 1Recruiting: 1Not Yet Recruiting: 1Active: 1
Active Trials (2)
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
NCT05626712Type 1 Diabetes
Phase 1Phase 2Recruiting
Enrollment: 18 participants
Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
NCT06053242Chronic Low-back Pain
Phase 1Phase 2Active
Enrollment: 45 participants
Key Facts
Market Cap$1.6M
Employees4 (+0% YoY)
CEOTimothy Warbington
IPO DateNov 6, 2015
Beta1.95
52-Week Range$0.5901 – $4.72
Avg Volume4,949,375
ExchangeNASDAQ
Ownership
Float92.4%
Shares Outstanding2.6M
Recent Insider Trades
Warbington TimothyAWARD
Sep 24, 20261,000,000 shares @ $200000.00
Finger Michael H.SELL
Feb 18, 2025750 shares @ $5.00
Finger Michael H.SELL
Feb 19, 2025750 shares @ $5.75
Warbington TimothyBUY
Jun 28, 2023200 shares @ $4.36
Warbington TimothyBUY
Jun 27, 2023200 shares @ $4.48
Peers
Recent News
Creative Medical Technology Holdings Highlights 93% Patient Response Rate and 65% Reduction in Average Pain Scores in Ultrasome™ Knee Osteoarthritis Study
Oct 20, 2026 · globenewswire.com
Head to Head Analysis: Creative Medical Technology (NASDAQ:CELZ) versus Grifols (NASDAQ:GRFS)
Sep 30, 2026 · defenseworld.net
Creative Medical Technology (NASDAQ:CELZ) & argenex (NASDAQ:ARGX) Head to Head Analysis
Sep 25, 2026 · defenseworld.net
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
Sep 17, 2026 · globenewswire.com
Critical Contrast: Creative Medical Technology (NASDAQ:CELZ) vs. CRISPR Therapeutics (NASDAQ:CRSP)
Sep 8, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:01 AM